News Column

ISIS PHARMACEUTICALS INC FILES (8-K) Disclosing Submission of Matters to a Vote of Security Holders

June 13, 2014



Item 5.07. Submission of Matters to a Vote of Security Holders.

Isis Pharmaceuticals, Inc. held its Annual Meeting of Stockholders on June 10, 2014. The stockholders considered seven proposals, each of which is described in more detail in the Company's definitive proxy statement filed with SEC on April 25, 2014.

Proposal 1: Election of directors to hold office until the 2017 Annual Meeting:

BROKER FOR WITHHELD ABSTAIN NON-VOTES Spencer R. Berthelsen 78,751,555 2,153,826 3,516,027 17,393,063 B. Lynne Parshall 80,051,508 1,029,353 3,340,547 17,393,063 Joseph H. Wender 82,120,552 771,040 1,529,816 17,393,063



The Company's stockholders elected the foregoing candidates, by affirmative votes by a majority of the votes of the shares represented in person or by proxy at the meeting and entitled to vote in the election of Directors.

Proposal 2: Ratification of the appointment of a director to hold office until

the 2015 Annual Meeting: BROKER FOR WITHHELD ABSTAIN NON-VOTES Breaux Castleman 82,210,674 2,070,994 139,740 17,393,063



The Company's stockholders ratified Mr. Castleman's appointment by affirmative votes by a majority of the votes of the shares represented in person or by proxy at the meeting and entitled to vote in the election of a Director.

Proposal 3: Ratification of the appointment of a director to hold office until

the 2016 Annual Meeting: BROKER FOR WITHHELD ABSTAIN NON-VOTES



Joseph Loscalzo 83,815,199 464,623 141,586 17,393,063

The Company's stockholders ratified Dr. Loscalzo's appointment by affirmative votes by a majority of the votes of the shares represented in person or by proxy at the meeting and entitled to vote in the election of a Director.

Proposal 4: Amendment to the Isis Pharmaceuticals, Inc. Restated Certificate of Incorporation FOR AGAINST ABSTAIN BROKER NON-VOTES 96,941,381 3,611,772 1,261,318 0



The Company's stockholders approved the foregoing proposal.

--------------------------------------------------------------------------------

Proposal 5: Approve an amendment to the Isis Pharmaceuticals, Inc. 2002

Non-Employee Directors' Stock Option Plan FOR AGAINST ABSTAIN BROKER NON-VOTES 80,304,735 3,966,102 150,571 17,393,063



The Company's stockholders approved the foregoing proposal.

Proposal 6: Approval, on an advisory basis, of the compensation paid to the

Company's executive officers, including the following resolution:



"RESOLVED, that Isis' stockholders approve, on an advisory basis, the compensation of the named executive officers, as disclosed in this Proxy Statement for the 2014 Annual Meeting of Stockholders pursuant to the compensation disclosure rules of the Securities and Exchange Commission."

FOR AGAINST ABSTAIN BROKER NON-VOTES 83,325,374 884,405 211,629 17,393,063



The Company's stockholders approved the foregoing proposal.

Proposal 7: Ratify the Audit Committee's selection of Ernst & Young LLP as

independent auditors for our 2014 fiscal year: FOR AGAINST ABSTAIN BROKER NON-VOTES 100,326,491 1,144,920 343,060 0



The Company's stockholders approved the foregoing proposal.

--------------------------------------------------------------------------------


For more stories on investments and markets, please see HispanicBusiness' Finance Channel



Source: Edgar Glimpses


Story Tools






HispanicBusiness.com Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters